Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Shin Nippon Biomedical Laboratories’ subsidiary, Satsuma Pharmaceuticals, has received FDA acceptance for the resubmission of its NDA for STS101, a novel treatment for acute migraine. This milestone aligns with SNBL’s financial forecasts for the fiscal year ending March 2025, as the U.S. market for such treatments exceeds $1 billion.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.